CYTK
CYTK
NASDAQ · Biotechnology

Cytokinetics Inc

$76.91
+2.62 (+3.53%)
As of May 9, 1:13 AM ET ·
Financial Highlights (FY 2026)
Revenue
91.46M
Net Income
-815,474,440
Gross Margin
Profit Margin
-891.6%
Rev Growth
-2.4%
D/E Ratio
0.59
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 41.7% 41.7%
Operating Margin -833.2% -749.8% 29.1% 29.0%
Profit Margin -891.6% -847.0% 18.4% 22.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 91.46M 93.68M 617.31M 631.19M
Gross Profit 257.41M 263.20M
Operating Income -761,992,380 -702,440,993 179.75M 183.04M
Net Income -815,474,440 -751,743,312 113.32M 141.95M
Gross Margin 41.7% 41.7%
Operating Margin -833.2% -749.8% 29.1% 29.0%
Profit Margin -891.6% -847.0% 18.4% 22.5%
Rev Growth -2.4% -2.4% +3.9% +23.4%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 1.78B 1.78B 602.04M 772.62M
Total Equity 3.02B 3.02B 2.97B 3.11B
D/E Ratio 0.59 0.59 0.20 0.25
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -751,715,786 -731,465,734 314.99M 272.50M
Free Cash Flow 143.60M 140.08M